Dr. Jennifer Marquez is ready to assist you in your medical practice. Her passion is helping both patients and their healthcare providers to optimize drug therapy. Please feel free to request a visit to your practice to learn about all the benefits that PharmDNA, LLC can offer you, your practice, and your patients. We are eager to meet with you if you want to learn more!
There is a rapidly-growing body of robust literature supporting the implementation of PGx into clinical practice. The Clinical Pharmacogenetics Implementation Consortium (CPIC) produces guidelines that are peer-reviewed, regularly updated, and freely available (see link below) to guide drug therapy with certain gene-drug pairs in the presence of certain genetic variants. Many of these gene-drug pairs and genetic variants are well-studied, clinically significant and actionable in everyday medical practice.
Dr. Jennifer Marquez is trained to analyze and interpret the data in the 20-40 page genetic reports that result from PGx testing, as well as the related gene-drug pair guidelines and complexities of drug-gene, drug-drug, and drug-drug-gene interactions. Drug-drug-gene interactions can be very complex, and sometimes adding a second drug that interacts with a certain gene will cause something called phenoconversion to occur. This is a phenomenon that converts genotypic extensive metabolizers into phenotypic poor metabolizers of drugs.
A few links and references are posted here for your convenience and review.
2021 meta analysis showing PGx reduces hospitalizations (pdf)Download
2021 article about integrating PGx into CMM models (pdf)Download
2020 article highlighting the benefits of PGx implementation at University of Colorado (pdf)Download
2020 PGx in cardiovascular disease article (pdf)Download
2020 PGx in depression article (pdf)Download
PGx improves health system performance (pdf)Download
Dr. Jennifer Marquez
Founder/CEO of PharmDNA, LLC
Copyright © 2022 PharmDNA, LLC - All Rights Reserved.